Titan Pharmaceuticals Inc
TTNP3.850USD
-0.140-3.51%
Market hours （ET）Quotes delayed by 15 min
3.52MMarket Cap
LossP/E TTM
More Details of Titan Pharmaceuticals Inc Company
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Company Info
Ticker SymbolTTNP
Company nameTitan Pharmaceuticals Inc
IPO dateJan 18, 1996
CEOMr. Weei Jye Chay
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 18
AddressSuite 505
CitySAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone14152444990
Websitehttps://www.titanpharm.com/
Ticker SymbolTTNP
IPO dateJan 18, 1996
CEOMr. Weei Jye Chay
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
Independent Director
Independent Director
3.31K
--
Mr. Gabriel Loh
Mr. Gabriel Loh
Independent Director
Independent Director
--
--
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Brynner Chiam
Mr. Brynner Chiam
Acting Principal Financial Officer, Director
Acting Principal Financial Officer, Director
--
--
Mr. Firdauz Edmin Bin Mokhtar, CPA
Mr. Firdauz Edmin Bin Mokhtar, CPA
Independent Director
Independent Director
--
--
Mr. Francisco Osvaldo Flores Garcia
Mr. Francisco Osvaldo Flores Garcia
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
Independent Director
Independent Director
3.31K
--
Mr. Gabriel Loh
Mr. Gabriel Loh
Independent Director
Independent Director
--
--
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Brynner Chiam
Mr. Brynner Chiam
Acting Principal Financial Officer, Director
Acting Principal Financial Officer, Director
--
--
Mr. Firdauz Edmin Bin Mokhtar, CPA
Mr. Firdauz Edmin Bin Mokhtar, CPA
Independent Director
Independent Director
--
--
Mr. Francisco Osvaldo Flores Garcia
Mr. Francisco Osvaldo Flores Garcia
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
Citadel Advisors LLC
0.90%
Geode Capital Management, L.L.C.
0.52%
Other
49.15%
Shareholders
Shareholders
Proportion
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
Citadel Advisors LLC
0.90%
Geode Capital Management, L.L.C.
0.52%
Other
49.15%
Shareholder Types
Shareholders
Proportion
Individual Investor
29.69%
Corporation
19.99%
Hedge Fund
0.90%
Investment Advisor/Hedge Fund
0.54%
Investment Advisor
0.51%
Other
48.38%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
40
414.53K
44.46%
-42.07K
2025Q1
46
436.25K
42.35%
-38.12K
2024Q4
45
429.27K
46.95%
-32.22K
2024Q3
46
432.62K
47.32%
-13.85K
2024Q2
51
448.01K
49.00%
-8.81K
2024Q1
52
447.94K
49.00%
-53.81K
2023Q4
49
450.14K
59.78%
+330.86K
2023Q3
57
298.19K
41.35%
-95.76K
2023Q2
53
281.88K
39.24%
-113.75K
2023Q1
57
262.38K
36.64%
-134.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Choong (Choon Hau)
241.53K
18.16%
--
--
Apr 21, 2025
Chung (Jeffrey)
143.84K
10.81%
+143.84K
--
Mar 12, 2025
Citadel Advisors LLC
11.96K
0.9%
+11.96K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
6.91K
0.52%
--
--
May 31, 2025
The Vanguard Group, Inc.
4.10K
0.31%
--
--
May 31, 2025
Ben-Tzvi (Avraham)
3.31K
0.25%
--
--
Apr 21, 2025
UBS Financial Services, Inc.
2.59K
0.2%
-73.00
-2.74%
Mar 31, 2025
Northern Trust Investments, Inc.
129.00
0.01%
+129.00
--
Dec 31, 2023
Corecap Advisors Inc
88.00
0.01%
+88.00
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Date
Type
Ratio
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
Nov 30, 2020
Merger
30<1
